Aquinox Pharmaceuticals Inc. (AQXP) is one of Thursday’s notable stocks in decline, down 24.05% to $6.00. The nosedive is attributed to results from the company’s Phase 2 LEADERSHIP randomized clinical trial investigating the therapeutic potential of AQX-1125 in treating pain in patients with bladder pain syndrome/interstitial cystitis (BPS/IC).
Aquinox said that while AQX-1125 demonstrated a reduction in pain for patients on AQX-1125 as compared to those patients on placebo following six weeks of treatment, the difference did not reach statistical significance (p = 0.061).
Shares of Exact Sciences Corp. (EXAS) are trading down nearly 16% in Thursday morning trading. The company today announced that it expects to end Q2/15 with 21,000 completed Cologuard tests. Exact anticipates completing approximately 32,000 tests during the third quarter of 2015.
“The launch of Cologuard remains very strong and we continue to invest in its growth,” stated Kevin T. Conroy, chairman and CEO of Exact Sciences.
Humana Inc. (HUM) jumps 15 points to $199.98 in midday trading as speculation of Aetna Inc. (AET) nearing an offer intensifies. Bloomberg News reports the company has received a cash/stock offer from Aetna with likely value of over $28 billion and that the deal could close as early as this weekend. The report also says Humana received offer from Cigna Corp (CI) but favors Aetna. The Journal reported last weekend that Aetna has offered to purchase Humana for an unknown amount.